Cargando…

Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis

Histomoniasis, caused by the protozoan parasite Histomonas meleagridis, is a disease to which turkeys are especially susceptible. Currently, no chemoprophylaxis compounds are available to mitigate this disease. Boric acid (BA) exhibits antifungal, antiseptic, and antiviral properties and has been us...

Descripción completa

Detalles Bibliográficos
Autores principales: Beer, L.C., Vuong, C.N., Barros, T.L., Latorre, J.D., Tellez, G., Fuller, A.L., Hargis, B.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587612/
https://www.ncbi.nlm.nih.gov/pubmed/32241479
http://dx.doi.org/10.1016/j.psj.2019.12.003
_version_ 1783600210014896128
author Beer, L.C.
Vuong, C.N.
Barros, T.L.
Latorre, J.D.
Tellez, G.
Fuller, A.L.
Hargis, B.M.
author_facet Beer, L.C.
Vuong, C.N.
Barros, T.L.
Latorre, J.D.
Tellez, G.
Fuller, A.L.
Hargis, B.M.
author_sort Beer, L.C.
collection PubMed
description Histomoniasis, caused by the protozoan parasite Histomonas meleagridis, is a disease to which turkeys are especially susceptible. Currently, no chemoprophylaxis compounds are available to mitigate this disease. Boric acid (BA) exhibits antifungal, antiseptic, and antiviral properties and has been used in the treatment of yeast infections. Based on these characteristics, an experiment was conducted to evaluate whether BA might be an efficacious prophylaxis against challenge with wild-type H. meleagridis (WTH). On day-of-hatch, poults were randomly assigned to either a basal control diet or a BA diet (basal diet + 0.2% BA). Groups consisted of a nonchallenged control (NC; basal diet), 0.2% BA + challenge (BA; 0.2% BA diet), and a positive-challenged control (PC; basal diet). On day 21, challenged groups were intracloacally inoculated with 2 × 10(5) WTH cells/turkey, and lesions were evaluated on day 14 postchallenge. Individual body weights were recorded on day 0, 21, and 35 to calculate the prechallenge and postchallenge body weight gain (BWG). The BA group resulted in lower prechallenge day 0 to day 21 BWG (P = 0.0001) than the NC group. Postchallenge day 21 to day 35, BWG was also lower (P = 0.0503) in the BA group than the PC group. No differences between the BA and PC groups were detected for mortalities associated with histomoniasis. Moreover, liver and cecal lesions were not statistically different between the BA and PC groups. Taken together, these data suggest that BA was not efficacious in the prevention or reduction of histomoniasis disease severity when provided at 0.2% dietary concentration under these experimental conditions.
format Online
Article
Text
id pubmed-7587612
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75876122020-10-27 Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis Beer, L.C. Vuong, C.N. Barros, T.L. Latorre, J.D. Tellez, G. Fuller, A.L. Hargis, B.M. Poult Sci Immunology, Health and Disease Histomoniasis, caused by the protozoan parasite Histomonas meleagridis, is a disease to which turkeys are especially susceptible. Currently, no chemoprophylaxis compounds are available to mitigate this disease. Boric acid (BA) exhibits antifungal, antiseptic, and antiviral properties and has been used in the treatment of yeast infections. Based on these characteristics, an experiment was conducted to evaluate whether BA might be an efficacious prophylaxis against challenge with wild-type H. meleagridis (WTH). On day-of-hatch, poults were randomly assigned to either a basal control diet or a BA diet (basal diet + 0.2% BA). Groups consisted of a nonchallenged control (NC; basal diet), 0.2% BA + challenge (BA; 0.2% BA diet), and a positive-challenged control (PC; basal diet). On day 21, challenged groups were intracloacally inoculated with 2 × 10(5) WTH cells/turkey, and lesions were evaluated on day 14 postchallenge. Individual body weights were recorded on day 0, 21, and 35 to calculate the prechallenge and postchallenge body weight gain (BWG). The BA group resulted in lower prechallenge day 0 to day 21 BWG (P = 0.0001) than the NC group. Postchallenge day 21 to day 35, BWG was also lower (P = 0.0503) in the BA group than the PC group. No differences between the BA and PC groups were detected for mortalities associated with histomoniasis. Moreover, liver and cecal lesions were not statistically different between the BA and PC groups. Taken together, these data suggest that BA was not efficacious in the prevention or reduction of histomoniasis disease severity when provided at 0.2% dietary concentration under these experimental conditions. Elsevier 2020-01-24 /pmc/articles/PMC7587612/ /pubmed/32241479 http://dx.doi.org/10.1016/j.psj.2019.12.003 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Immunology, Health and Disease
Beer, L.C.
Vuong, C.N.
Barros, T.L.
Latorre, J.D.
Tellez, G.
Fuller, A.L.
Hargis, B.M.
Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis
title Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis
title_full Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis
title_fullStr Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis
title_full_unstemmed Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis
title_short Research Note: Evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis
title_sort research note: evaluation of boric acid as a chemoprophylaxis candidate to prevent histomoniasis
topic Immunology, Health and Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587612/
https://www.ncbi.nlm.nih.gov/pubmed/32241479
http://dx.doi.org/10.1016/j.psj.2019.12.003
work_keys_str_mv AT beerlc researchnoteevaluationofboricacidasachemoprophylaxiscandidatetopreventhistomoniasis
AT vuongcn researchnoteevaluationofboricacidasachemoprophylaxiscandidatetopreventhistomoniasis
AT barrostl researchnoteevaluationofboricacidasachemoprophylaxiscandidatetopreventhistomoniasis
AT latorrejd researchnoteevaluationofboricacidasachemoprophylaxiscandidatetopreventhistomoniasis
AT tellezg researchnoteevaluationofboricacidasachemoprophylaxiscandidatetopreventhistomoniasis
AT fulleral researchnoteevaluationofboricacidasachemoprophylaxiscandidatetopreventhistomoniasis
AT hargisbm researchnoteevaluationofboricacidasachemoprophylaxiscandidatetopreventhistomoniasis